
Extensively published in
leading scientific journals
Resources
-
Videos
Go to Videos
-
Test Reports
Download Decipher sample test reports
-
Requisitions
Download test requisitions & specimen instructions
-
Decipher Assist
Download Decipher Assist guides and forms
-
Licenses
Download Veracyte Labs SD Licenses
-
Patient Brochure
Download Patient Brochure
-
LCD
Local Coverage Determination
Publications
Decipher Prostate Genomic Classifier
Post-Biopsy
- Awasthi S, et al. Genomic testing in localized prostate cancer can identify subsets of African-Americans with aggressive disease. J Natl Cancer Inst 2022.
- Parry, M. et al. 1358O Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial. Ann Oncol 2022; 33: S1161.
- Press BH, et al. Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. Eur Urol Open Sci 2022; 37: 113-119.
- Spratt DE, et al. Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126. J Clin Oncol 2022; 40 (6_suppl): 269.
- Feng FY, et al. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Oncol 2021; 7: 1005-1014.
- Hamid AA et al. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED study. Ann Oncol 2021.
- Nguyen PL, et al. Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2021; 111: S50.
- Punnen S, et al. Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy. J Urol 2021; 205: 1344-1351.
- Vince RA Jr. et al. Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. Prostate Cancer Prostatic Dis 2021.
- Goldberg H, et al. Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease. Eur Urol Focus 2020.
- Feng FY, et al. Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN. J Clin Oncol 2020; 38: 5535-5535.
- Herlemann, A et al. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis 2020; 23: 136-143.
- Tosoian JJ, et al. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer Prostatic Dis 2020; 23: 646-653.
- Berlin A, et al. Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. Int J Radiat Oncol Biol Phys 2019; 103(1): 84-91.
- Falagario UG, et al. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests. J Urol 2019; 202(1): 102-07.
- Kim HL, et al. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer Prostatic Dis 2019; 22(3): 399-405.
- Martin DT, et al. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies. Urology 2019; 125: 64-72.
- Muralidhar V, et al. Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2019; 105: 621-627.
- Purysko AS, et al. Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. Eur Radiol 2019; 29(9): 4861-70.
- Van den Broeck T, et al. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. Eur Urol Oncol 2019; 2(5): 589-96.
- Xu MJ, et al. Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. Eur Urol Oncol 2019; 2: 685-690.
- Beksac AT, et al. Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level. J Urol 2018; 200(6): 1241-49.
- Cooperberg MR, et al. The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. Eur Urol 2018; 74(4): 444-52.
- Hu JC, et al. Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. JCO Precision Oncology 2018; 2: 1-15.
- Radtke JP, et al. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit. Eur Urol Focus 2018; 4(4): 540-46.
- Spratt DE, et al. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol 2018; 36(6): 581-90.
- Klein EA, et al. Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. J Urol 2017; 197(1): 122-28.
- Nguyen PL, et al. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol 2017; 72(5): 845-52.
- Nguyen PL, et al. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis 2017; 20(2): 186-92.
- Klein EA, et al. Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. Urology 2016; 90: 148-52.
- Knudsen BS, et al. Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. J Mol Diagn 2016; 18(3): 395-406.
- Lee HJ, et al. Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis. Res Rep Urol 2016; 8: 77-84.
- Stoyanova R, et al. Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. Oncotarget 2016; 7(33): 53362-76.
Post-Radical Prostatectomy
- Dal Pra A, et al. Validation of the Decipher Genomic Classifier in Patients receiving Salvage Radiotherapy without Hormone Therapy after Radical Prostatectomy – An Ancillary Study of the SAKK 09/10 Randomized Clinical Trial. Ann Oncol 2022; 33(9): 950-958.
- Lone Z, et al. Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate. Eur Urol Focus 2022; S2405-4569(22)00125-0.
- Ramotar M, et al. Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. Urol. Oncol. 2022; 40 (1): 5.e1-5.e13.
- Feng FY, et al. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol 2021.
- Lee DI, et al. External validation of genomic classifier-based risk-stratification tool to identify candidates for adjuvant radiation therapy in patients with prostate cancer. World J Urol 2021.
- Li L, et al. A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI. EBioMedicine 2021; 63: 103163.
- Shahait M, et al. Impact of Decipher on use of post-operative radiotherapy: Individual patient analysis of two prospective registries. BJU Int 2021; 00: 1-8.
- Gore JL, et al. Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. Pract Radiat Oncol 2020; 10: e82-e90.
- Howard LE, et al. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. Prostate Cancer Prostatic Dis 2020; 23: 419-428.
- Kishan AU, et al. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Eur Urol 2020; 78: 327-332.
- Marascio J, et al. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer Prostatic Dis 2020; 23: 295-302.
- Jambor I, et al. Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score. J Magn Reson Imaging 2020; 51: 1075-1085.
- Taylor AS, et al. Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier. Prostate 2020; 80: 146-152.
- Martini A, et al. A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome. BJU Int 2019; 124(1): 155-62.
- Karnes RJ, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol 2018; 73(2): 168-75.
- Spratt DE, et al. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. Eur Urol 2018;74(1):107-14.
- Dalela D, et al. Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. J Clin Oncol 2017; 35(18): 1982-90.
- Gore JL, et al. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. Cancer 2017; 123(15): 2850-59.
- Lobo JM, et al. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. Clin Genitourin Cancer 2017; 15(3): e299-e309.
- Spratt DE, et al. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. J Clin Oncol 2017; 35(18): 1991-98.
- Den RB, et al. Decipher correlation patterns post prostatectomy: initial experience from 2,342 prospective patients. Prostate Cancer Prostatic Dis 2016; 19(4): 374-79.
- Freedland SJ, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur Urol 2016;70(4):588-96.
- Glass AG, et al. Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting. J Urol 2016; 195(6): 1748-53.
- Ross AE, et al. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. Eur Urol 2016; 69(1): 157-65.
- Ross AE, et al. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis 2016; 19(3): 277-82.
- Badani KK, et al. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. BJU Int 2015; 115(3): 419-29.
- Cooperberg MR, et al. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 2015; 67(2): 326-33.
- Den RB, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 2015; 33(8): 944-51.
- Klein EA, et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol 2015; 67(4): 778-86.
- Lobo JM, et al. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. PLoS One 2015; 10(3): e0116866.
- Nguyen PL, et al. Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. Urology 2015;86(1):35-40.
- Den RB, et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2014; 89(5): 1038-46.
- Michalopoulos SN, et al. Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study. Curr Med Res Opin 2014; 30(8): 1547-56.
- Ross AE, et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis 2014;17(1):64-9.
- Badani K, et al. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget 2013; 4(4): 600-9.
- Erho N, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013;8(6):e66855.
- Karnes RJ, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013;190(6):2047-53.
Decipher GRID (All)
- Chakravarty D, et al. Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer. Cancers (Basel) 2022; 14(11): 2734.
- Kensler KH, et al. Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. Eur Urol Open Sci 2022; 40: 19-26.
- Martini, A. et al. The Paradoxical Role of Body Mass Index in Patients with Muscle-invasive Bladder Cancer Receiving Neoadjuvant Immunotherapy. Eur Urol Oncol 2022; 5: 370-372.
- Qiu X, et al. MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nat Commun 2022; 13: 2559.
- Pryma C, et al. Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma. Virchows Arch 2022; 481: 397-403.
- Shahait, et al. Does Perioperative Testosterone Predict Post-Prostatectomy Genomic Risk Score? J Urol 2022.
- Van den Broeck, et al. Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer. Mol Cancer Res 2022.
- Weiner AB, et al. High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments. Prostate Cancer Prostatic Dis 2022;
- Yoshikawa Y, et al. Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. Mol Oncol 2022.
- Alshalalfa M, et al. Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation. J Cancer Res Clin Oncol 2021.
- Awasthi S, et al. Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res 2021; 27: 320-329.
- Chu CE, et al. Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. Eur Urol 2021.
- de Jong JJ, et al. Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology. Am J Clin Pathol 2021; 156: 895-905.
- Ding YC, et al. Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases. J Transl Genet Genom 2021; 5: 50-61.
- Grbesa I, et al. Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity. Cell Rep 2021; 36: 109625.
- Krentel F, et al. A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer. Sci Rep 2021; 11: 5849.
- Liu D, et al. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J Clin Invest 2021; 131.
- Mukhopadhyay C, et al. G3BP1 inhibits Cul3(SPOP) to amplify AR signaling and promote prostate cancer. Nat Commun 2021; 12: 6662.
- Rayford W, et al. Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Commun Biol 2021; 4: 670.
- Singh, et al. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun 2021.
- Todenhofer T, et al. Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma. Urol Oncol 2021.
- Vandekerkhove G, et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun 2021; 12:184.
- Weiner AB, et al. A transcriptomic model for homologous recombination deficiency in prostate cancer. Prostate Cancer Prostatic Dis 2021.
- Weiner AB, et al. Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nat Commun 2021; 12: 935.
- Yoon J, et al. A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer Prostatic Dis 2021.
- Bahler CD, et al. Predictors of Prostate-specific Membrane Antigen (PSMA/FOLH1) Expression in a Genomic Database. Urology 2020; 144: 117-122.
- Ben-Salem S, et al. Diversity in Androgen Receptor Action Among Treatment-naive Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. Eur Urol Open Sci 2020; 22: 34-44.
- Chipidza FE, et al. Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. Clin Genitourin Cancer 2020.
- Ferrari MG, et al. Identifying and treating ROBO1(-ve) /DOCK1(+ve) prostate cancer: An aggressive cancer subtype prevalent in African American patients. Prostate 2020; 80: 1045-1057.
- Mahal BA, et al. Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer 2020; 126(7): 1407-1412.
- Shoag J, et al. Prognostic value of the SPOP mutant genomic subclass in prostate cancer. Urol Oncol 2020; 38: 418-422.
- Tabrizi S, et al. Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. Int J Radiat Oncol Biol Phys 2020; 108: 936-940.
- Weiner AB, et al. Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy. Eur Urol Oncol 2020.
- Yamoah K, et al. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol 2020.
- Adams EJ, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature 2019;571(7765):408-12.
- Alshalalfa M, et al. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. Int J Cancer 2019; 145: 3453-3461.
- Alshalalfa M, et al. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. Eur Urol Oncol 2019;2(4):405-12.
- Berglund AE, et al. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. Prostate Cancer Prostatic Dis 2019; 22(2): 292-302.
- Boufaied N, et al. Development of a predictive model for stromal content in prostate cancer samples to improve signature performance. J Pathol 2019; 249: 411-424.
- Cato L, et al. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell 2019; 35(3): 401-13 e6.
- Chen WS, et al. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clin Cancer Res 2019; 25(14): 4290-99.
- Cheng A, et al. A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies. Prostate 2019; 79(14): 1589-96.
- Echevarria MI, et al. African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. J Urol 2019;202(2):247-55.
- Feng Y, et al. Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. BMC Genomics 2019;20(1):146.
- Gerke T, et al. Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev 2019;28(3):584-90.
- Hectors SJ, et al. Radiomics Features Measured with Multiparametric Magnetic Resonance Imaging Predict Prostate Cancer Aggressiveness. J Urol 2019;202(3):498-505.
- Hughes RM, et al. Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. Cancer Res 2019;79(14):3636-50.
- Labbe DP, et al. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat Commun 2019;10(4358).
- Mahal BA, et al. Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. Eur Urol 2019;75(6):1038-40.
- Ramnarine VR, et al. The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management. Eur Urol 2019; 76: 546-559.
- Sjostrom M, et al. Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer. J Clin Oncol 2019; 37: 3340-3349.
- Sjostrom M, et al. Comprehensive transcriptomic profiling identifies breast cancer patients who may be spared adjuvant systemic therapy. Clin Cancer Res 2019; 26: 171-182.
- Spratt DE, et al. Transcriptomic heterogeneity of androgen receptor (AR) activity defines a de novo low AR-active subclass in treatment naive primary prostate cancer. Clin Cancer Res 2019; 25: 6721-6730.
- Zhao SG, et al. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res 2019; 25(8): 2450-57.
- Zhao SG, et al. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst 2019; 111(3): 301-10.
- Abou-Ouf H, et al. Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer. J Cancer Res Clin Oncol 2018; 144(5): 883-91.
- Karnes RJ, et al. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clin Cancer Res 2018; 24(16): 3908-16.
- Liu D, et al. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precis Oncol 2018.
- Mahal BA, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018; 74(2): 146-54.
- Mo F, et al. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. Eur Urol 2018; 73(4): 524-32.
- Rai R, et al. Epigenetic analysis identifies factors driving racial disparity in prostate cancer. Cancer Reports 2018;2(2):e1153.
- Ramnarine VR, et al. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience 2018; 7(6).
- Rounbehler RJ, et al. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev 2018; 27(11): 1376-83.
- Salami SS, et al. Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 2018; 3(21).
- Sharma V, et al. Gene Expression Correlates of Site-specific Metastasis Among Men with Lymph Node Positive Prostate Cancer Treated With Radical Prostatectomy: A Case Series. Urology 2018; 112: 29-32.
- Todenhofer T, et al. Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. Mol Cancer Ther 2018; 17(12): 2746-55.
- Torres A, et al. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63. Prostate 2018; 78(12): 896-904.
- Winters BR, et al. Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol 2018; 36(7): 342 e7-42 e14.
- Yang L, et al. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine 2018; 31: 182-89.
- Alshalalfa M, et al. Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. Oncotarget 2017; 8(31): 50804-13.
- Benzon B, et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis 2017; 20(1): 28-35.
- Das R, et al. MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. Cancer Res 2017; 77(4): 1021-34.
- Flores IE, et al. Stress alters the expression of cancer-related genes in the prostate. BMC Cancer 2017; 17(1): 621.
- Guedes LB, et al. Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. Clin Cancer Res 2017; 23(16): 4693-703.
- Itkonen HM, et al. Lipid degradation promotes prostate cancer cell survival. Oncotarget 2017; 8(24): 38264-75.
- Kim H, et al. Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes. Cancer 2017; 123(12): 2240-47.
- Kiss B, et al. Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Sci Rep 2017; 7: 42713.
- Labbe DP, et al. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clin Cancer Res 2017; 23(22): 7072-83.
- Liang Y, et al. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. Cancer Res 2017; 77(20): 5479-90.
- McNair C, et al. Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene 2017; 36(12): 1655-68.
- Nouri M, et al. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget 2017; 8(12): 18949-67.
- Pellegrini KL, et al. Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. BJU Int 2017; 119(6): 961-67.
- Seiler R, et al. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. Eur Urol 2017; 72(1): 142-50.
- Torres A, et al. Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. J Mol Diagn 2017; 19(3): 475-84.
- Tsai HK, et al. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer 2017; 17(1): 759.
- Tse BWC, et al. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene 2017; 36(24): 3417-27.
- Urbanucci A, et al. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep 2017; 19(10): 2045-59.
- Wahl DR, et al. Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. Int J Radiat Oncol Biol Phys 2017; 98(4): 726-32.
- Wei L, et al. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. Eur Urol 2017; 71(2): 183-92.
- White NM, et al. Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer. Eur Urol 2017; 71(2): 257-66.
- Zhao SG, et al. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol 2017; 3(12): 1663-72.
- Evans JR, et al. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncol 2016; 2(4): 471-80.
- Faisal FA, et al. Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. Eur Urol 2016; 70(1): 14-17.
- Hu BR, et al. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate 2016; 76(6): 597-608.
- Hurley PJ, et al. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clin Cancer Res 2016; 22(2): 448-58.
- Johnson MH, et al. SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. J Urol 2016; 196(5): 1436-44.
- Kim H, et al. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urol Case Rep 2016; 9: 51-54.
- Spans L, et al. Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. Oncotarget 2016; 7(17): 24326-38.
- You S, et al. Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Res 2016; 76(17): 4948-58.
- Zhao SG, et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol 2016; 17(11): 1612-20.
- Zhao SG, et al. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. Clin Cancer Res 2016; 22(7): 1777-86.
- Alshalalfa M, et al. Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int 2015; 116(4): 556-67.
- Alshalalfa M, et al. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer. Biol Cell 2015; 107(7): 232-44.
- Goodwin JF, et al. DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell 2015; 28(1): 97-113.
- Hurley PJ, et al. Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. Cancer Res 2015; 75(20): 4322-34.
- Jager W, et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget 2015; 6(25): 21522-32.
- Tomlins SA, et al. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol 2015; 68(4): 555-67.
- Tsai H, et al. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clin Cancer Res 2015; 21(24): 5619-29.
- Yamoah K, et al. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. J Clin Oncol 2015; 33(25): 2789-96.
- Zhao SG, et al. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis 2015; 18(3): 229-36.
- Chakravarty D, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun 2014; 5: 5383.
- Kaushik AK, et al. Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res 2014; 13(2): 1088-100.
- Lalonde E, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol 2014; 15(13): 1521-32.
- Prensner JR, et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol 2014; 15(13): 1469-80.
- Prensner JR, et al. The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget 2014; 5(6): 1434-8.
- Prensner JR, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 2013; 45(11): 1392-8.
- Wiseman SM, et al. Whole-transcriptome profiling of thyroid nodules identifies expression-based signatures for accurate thyroid cancer diagnosis. J Clin Endocrinol Metab 2013; 98(10): 4072-9.
- Erho N, et al. Transcriptome-wide detection of differentially expressed coding and non-coding transcripts and their clinical significance in prostate cancer. J Oncol 2012; 2012: 541353.
- Hurley PJ, et al. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A 2012;109(37):14977-82.
- Knudsen ES, et al. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat 2012; 133(3): 1009-24.
- Vergara IA, et al. Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers. Front Genet 2012; 3: 23.
- Abdueva D, et al. Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays. J Mol Diagn 2010; 12(4): 409-17.
Decipher Bladder
- Basile, G. et al. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial. Clin Cancer Res 2022.
- Chou, J. et al. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol 2022.
- Chu CE, et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin Cancer Res 2021; 27 (18): 5123-5130.
- Krentel, F. et al. A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer. Sci Rep 2021; 11: 5849.
- Lotan, Y. et al. Patients With Muscle Invasive Bladder Cancer with Non-luminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. J Urol 2021: 101097JU0000000000002261.
- Necchi A, et al. Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. Urol Oncol 2021; 39: 734 e711-734 e717.
- Necchi, A. et al. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. Eur Urol 2021.
- Bandini, M et al. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study*. Ann Oncol 2020; 31: 1755-1763.
- de Jong JJ, et al. A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Upstaging. J Urol 2020; 204: 239-246.
- de Jong JJ, et al. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. Eur Urol Oncol 2020.; 3 (4): 420-423.
- Grivas P, et al. Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. Urol Oncol 2020; 38: 262-268.
- Necchi A, et al. Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. Eur Urol Oncol 2020.
- Necchi A, et al. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. Eur Urol 2020.
- Batista da Costa J, et al. Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clin Cancer Res 2019;25(13):3908-20.
- de Jong JJ, et al. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Genome Med 2019;11(1):60.
- Efstathiou JA, et al. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. Eur Urol 2019;76(1):59-68.
- Genitsch V, et al. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urol Oncol 2019;37(9):573 e19-73 e29.
- Grivas P, et al. Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. Urol Oncol 2019.
- Lotan Y, et al. Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. Eur Urol 2019;76(2):200-06.
- Narayan VM, et al. Genomic Analysis and Treatment Response of a Bladder Urothelial Carcinoma With Sarcomatoid Variant Histology. Clin Genitourin Cancer 2019;17(5):e888-e92.
- Seiler R, et al. Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clin Cancer Res 2019;25(16):5082-93.
- Seiler R, et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol 2017;72(4):544-54.
- Seiler R, et al. Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. J Urol 2016;196(4):1036-41.
- Mitra AP, et al. Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer. J Natl Cancer Inst 2014;106(11):dju290.
Reviews Including Decipher
- Ahmed, M. E. et al. Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers. Eur Urol Focus 2022; 8: 663-666.
- Sutera, P. et al. Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate 2022; 82 Suppl 1, S73-S85.
- Banerjee et al. A review on the role of tissue-based molecular biomarkers for active surveillance. World J Urol 2021.
- Jairath, NK et al. A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol 2021; 79: 374-383.
- Nowroozi, A et al. Adjuvant vs. salvage Radiation Therapy after Radical Prostatectomy: Role of Decipher(R) in the Era of Personalized Medicine. Urol J 2021.
- Vandekerkhove, G et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun 2021; 12: 184.
- Bronimann, S et al. An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer. Expert Rev Mol Diagn 2020; 20: 841-850.
- Duffy MJ. Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clin Chem Lab Med 2020;58(3):326-39.
- Jalanko, T et al. Genomic Subtyping in Bladder Cancer. Curr Urol Rep 2020; 21: 9.
- McKay RR, et al. Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. Am Soc Clin Oncol Educ Book 2020;40:1-12.
- Necchi, A et al. Converging Roads to Early Bladder Cancer. Eur Urol 2020; 78: 127-130.
- Norris, JM et al. Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis. BMJ Open 2020; 10: e034611.
- Alam S, et al. Prostate cancer genomics: comparing results from three molecular assays. Can J Urol 2019;26(3):9758-62.
- Al Hussein Al Awamlh B, et al. Genomics and risk stratification in high-risk prostate cancer. Nat Rev Urol 2019;16(11):641-42.
- Al-Salama ZT. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer. Drugs 2019;79(14):1591-98.
- Cozar JM, et al. The role of miRNAs as biomarkers in prostate cancer. Mutat Res 2019;781:165-74.
- Creed JH, et al. Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk. Cancer Epidemiol Biomarkers Prev 2019.
- Eggener SE, et al. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol 2019:JCO1902768.
- Fine ND, et al. Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer. BJU Int 2019.
- Goldenberg SL, et al. A new era: artificial intelligence and machine learning in prostate cancer. Nat Rev Urol 2019;16(7):391-403.
- Kohaar I, et al. A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges. Int J Mol Sci 2019;20(8).
- McCormick BZ, et al. Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies. Indian J Urol 2019;35(1):6-17.
- Schulster M. Bladder Cancer Academy 2019 Selected Summaries. Rev Urol 2019;21(1):23-28.
- Vince RA, Jr., et al. Tissue-based genomics: which test and when. Curr Opin Urol 2019;29(6):598-604.
- Zumsteg ZS, Spratt DE. Precision Medicine for Localized Prostate Cancer: Time to Move Beyond NCCN Risk Stratification? Int J Radiat Oncol Biol Phys 2019;103(1):92-94.
- Carneiro A, et al. Are localized prostate cancer biomarkers useful in the clinical practice? Tumour Biol 2018;40(9):1010428318799255.
- Cucchiara V, et al. Genomic Markers in Prostate Cancer Decision Making. Eur Urol 2018;73(4):572-82.
- da Costa JB, et al. Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy. Urol Oncol 2018.
- Gadzinski AJ, Cooperberg MR. Prostate Cancer Markers. Cancer Treat Res 2018;175:55-86.
- Kornberg Z, et al. Genomic biomarkers in prostate cancer. Transl Androl Urol 2018;7(3):459-71.
- Kristiansen G. Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer. Mod Pathol 2018;31(S1):S143-55.
- Lamy PJ, et al. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. Eur Urol Focus 2018;4(6):790-803.
- Loeb S, Tosoian JJ. Biomarkers in active surveillance. Transl Androl Urol 2018;7(1):155-59.
- Olleik G, et al. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. J Natl Compr Canc Netw 2018;16(11):1340-51.
- Kim SP, et al. Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists. Urol Oncol 2018;36(11):501 e15-01 e21.
- Spratt DE, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol 2018;73(2):156-65.
- Teo MY, et al. Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nat Rev Clin Oncol 2018;15(3):150.
- Tilki D, Evans CP. The Decipher Genomic Classifier Independently Improves Prognostication for Patients After Prostatectomy. Eur Urol 2018;73(2):176-77.
- Alford AV, et al. The Use of Biomarkers in Prostate Cancer Screening and Treatment. Rev Urol 2017;19(4):221-34.
- Clinton TN, et al. Tissue-based biomarkers in prostate cancer. Expert Rev Precis Med Drug Dev 2017;2(5):249-60.
- Colicchia M, et al. Genomic tests to guide prostate cancer management following diagnosis. Expert Rev Mol Diagn 2017;17(4):367-77.
- Dall'Era M, Evans C. Genomic and Biological Markers to Select Treatment for Patients with Prostate Cancer: Choose Wisely, My Friend. J Urol 2017;197(1):8-9.
- Kretschmer A, Tilki D. Biomarkers in prostate cancer - Current clinical utility and future perspectives. Crit Rev Oncol Hematol 2017;120:180-93.
- Kretschmer A, et al. [Molecular biomarkers and prognostic factors for prostate cancer]. Urologe A 2017;56(7):933-44.
- Loeb S, Ross AE. Genomic testing for localized prostate cancer: where do we go from here? Curr Opin Urol 2017;27(5):495-99.
- Reichard CA, Klein EA. Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease. Nat Rev Urol 2017;14(1):59-64.
- Spratt DE. Performance and Utility of Prognostic Genomic Biomarkers After Prostatectomy: Decipher-ing the Data. J Clin Oncol 2017;35(25):2977-78.
- Dalela D, et al. Contemporary Role of the Decipher(R) Test in Prostate Cancer Management: Current Practice and Future Perspectives. Rev Urol 2016;18(1):1-9.
- De Marzo AM, et al. Premalignancy in Prostate Cancer: Rethinking What we Know. Cancer Prev Res 2016;9(8):648-56.
- Gaudreau PO, et al. The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomark Cancer 2016;8(Suppl 2):15-33.
- Martin NE. New developments in prostate cancer biomarkers. Curr Opin Oncol 2016;28(3):248-52.
- Morlacco A, Karnes RJ. Early salvage radiation therapy post-prostatectomy: key considerations. Future Oncol 2016;12(22):2579-87.
- Moschini M, et al. Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. BMC Med 2016;14:67.
- Na R, et al. Clinically available RNA profiling tests of prostate tumors: utility and comparison. Asian J Androl 2016;18(4):575-9.
- Pisansky TM. Salvage Radiotherapy for Postoperative Biochemical Failure of Prostate Cancer: The Path Toward Personalized Medicine. Eur Urol 2016;70(4):597-98.
- Reiter RE. Risk stratification of prostate cancer 2016. Scand J Clin Lab Invest Suppl 2016;245:S54-9.
- Ross AE, D'Amico AV, Freedland SJ. Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis 2016;19(1):1-6.
- Ross AE, et al. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. Eur Urol 2016;69(3):496-504.
- Sharma P, Zargar-Shoshtari K, Pow-Sang JM. Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA 2016;2(1):FSO72.
- Stoyanova R, et al. Prostate cancer radiomics and the promise of radiogenomics. Transl Cancer Res 2016;5(4):432-47.
- Zhuang L, Johnson MT. How Precisely Can Prostate Cancer Be Managed? Int Neurourol J 2016;20(Suppl 2):S120-30.
- Bostrom PJ, et al. Genomic Predictors of Outcome in Prostate Cancer. Eur Urol 2015;68(6):1033-44.
- Davis J. Use of genomic markers to risk stratify men with prostate cancer. Trends in Urology & Men's Health 2015;6(3):36-39.
- Falzarano SM, et al. Novel biomarkers and genomic tests in prostate cancer: a critical analysis. Minerva Urol Nefrol 2015;67(3):211-31.
- Marrone M, et al. A 22 Gene-expression Assay, Decipher(R) (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical Prostatectomy. PLoS Curr 2015;7.
- Nguyen HG, Welty CJ, Cooperberg MR. Diagnostic associations of gene expression signatures in prostate cancer tissue. Curr Opin Urol 2015;25(1):65-70.
- Spahn M, et al. What is the Need for Prostatic Biomarkers in Prostate Cancer Management? Curr Urol Rep 2015;16(10):70.
- Davis JW. Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact. BJU Int 2014;114(3):320-2.